Three-dimensional nanostructured substrates toward efficient capture of circulating tumor cells.
Three-dimensional nanostructured substrates toward efficient capture of circulating tumor cells.
复制标题
DOI：
10.1002/anie.200901668
复制
发表时间：
2009
影响因子：
16.6
通讯作者：
Tseng, Hsian-Rong
中科院分区：
文献类型：
--
作者：
Wang, Shutao;Wang, Hao;Jiao, Jing;Chen, Kuan-Ju;Owens, Gwen E.;Kamei, Ken-ichiro;Sun, Jing;Sherman, David J.;Behrenbruch, Christian P.;Wu, Hong;Tseng, Hsian-Rong
在转移的进展过程中，癌细胞从实体原发性肿瘤分离，进入血流，并移动到身体的不同组织。这些在外周血中分离的癌细胞被称为循环肿瘤细胞（CTC）。[1]除了常规的诊断成像和血清标志物检测外，患者血液中CTC的定量提供了有关管理癌症的新的和有价值的信息。[2-5]在过去的十年中，CTC计数已被用于检查癌症转移，预测患者预后和监测癌症的治疗结果。[6]然而，由于血液中大量血液细胞（109 mL-1）中CTC的丰度极低（每毫升几个到几百个），CTC的分离在技术上具有挑战性。[4，7，8]已经开发了几种用于分离/计数CTC的技术平台，其策略涉及免疫磁珠或微流体装置。[3，4，9，10]前者利用捕获剂包被的磁珠免疫识别血液中的CTC，然后进行磁性分离。然而，这些基于珠粒的方法受到其低CTC捕获产率和纯度的限制。最近，已经建立了许多微流体技术[9，10]，用于从全血样品中捕获活的CTC，与基于珠的方法相比，其效率和选择性有所提高。[3，7]虽然在这些CTC分选微芯片中应用了不同的器件架构，通过增加CTC/基质接触频率和持续时间，可以提高CTC捕获效率。在此，我们证明了用上皮细胞粘附分子抗体包被的三维（3D）纳米结构基质（抗EpCAM）在用于从全血样品中分离活癌细胞时表现出突出的细胞捕获效率。我们预见这种新的细胞捕获平台可以为分离/计数CTC提供方便且具有成本效益的替代方案。EpCAM是一种跨膜糖蛋白，在多种实体瘤细胞中经常过表达，而在血液细胞中不存在。[11]这种新方法的独特性（图1a）在于使用3D纳米结构
During the progression of metastasis, cancer cells detach from the solid primary tumor, enter the blood stream, and travel to different tissues of the body. These breakaway cancer cells in the peripheral blood are known as circulating tumor cells (CTCs).[1] In addition to conventional diagnostic imaging and serum marker detection, quantification of CTCs in patient blood provides new and valuable information about managing cancer.[2–5] Over the past decade, CTC counting has been used for examining cancer metastasis, predicting patient prognosis, and monitoring the therapeutic outcomes of cancer.[6] However, isolation of CTCs has been technically challenging due to the extremely low abundance (a few to hundreds per milliliter) of CTCs among a large number of hematologic cells in the blood (109 mL− 1).[4, 7, 8] Several technology platforms for isolating/counting CTCs have been developed with strategies that involve immunomagnetic beads or microfluidic devices.[3, 4, 9, 10] The former utilizes capture-agent-coated magnetic beads to immunologically recognize CTCs in the blood, followed by magnetic isolation. However, these bead-based approaches are limited by their low CTC-capture yield and purity. Recently, a number of microfluidic technologies [9, 10] has been established for capturing viable CTCs from whole-blood samples with improved efficiency and selectivity compared to the bead-based approach.[3, 7] While different device architectures were applied in these CTC-sorting microchips, the improved CTC-capture efficiencies were achieved by increasing CTC/substrate contact frequency and duration.Herein we demonstrate that a three-dimensionally (3D) nanostructured substrate coated with epithelial-cell adhesion-molecule antibody (anti-EpCAM) exhibits outstanding cell-capture efficiency when employed to isolate viable cancer cells from whole-blood samples. We foresaw that this new cell capture platform could provide a convenient and cost-efficient alternative for isolating/counting CTCs. EpCAM is a transmembrane glycoprotein that is frequently overexpressed in a variety of solid-tumor cells and is absent from hematologic cells.[11] The uniqueness of this new approach (Figure 1a) lies in the use of 3D nanostructured
登录
查看更多内容
影响因子：
158.5
作者：
Cristofanilli, M;Budd, GT;Hayes, DF
通讯作者：
Hayes, DF
DOI：
10.1073/pnas.0404036101
发表时间：
2004-07-20
影响因子：
11.1
作者：
Krivacic, RT;Ladanyi, A;Bruce, RH
通讯作者：
Bruce, RH
影响因子：
10.8
作者：
Park, Jung;Bauer, Sebastian;Schmuki, Patrik
通讯作者：
Schmuki, Patrik
影响因子：
56.9
作者：
Lee, KB;Park, SJ;Mrksich, M
通讯作者：
Mrksich, M
影响因子：
29.4
作者：
Dang, Jiyoung M.;Leong, Kam W.
通讯作者：
Leong, Kam W.